When should we treat moderate hypoxaemia in patients with COPD? - Authors' reply

Affiliations

¹ Centre de recherche, Centre de pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, QC G1V 4G5, Canada. Electronic address: yves.lacasse@med.ulaval.ca.
² Rehabilitation Clinical Trials Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
³ Centre de recherche, Centre de pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, QC G1V 4G5, Canada.

Comment

Yves Lacasse et al. Lancet Respir Med. 2022 Nov.

. 2022 Nov;10(11):e98.

doi: 10.1016/S2213-2600(22)00357-5.

¹ Centre de recherche, Centre de pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, QC G1V 4G5, Canada. Electronic address: yves.lacasse@med.ulaval.ca.
² Rehabilitation Clinical Trials Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
³ Centre de recherche, Centre de pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, QC G1V 4G5, Canada.

No abstract available

Conflict of interest statement

Author declarations remain the same as in the original Article.

Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Lacasse Y, Casaburi R, Sliwinski P, Chaouat A, Fletcher E, Haidl P, Maltais F. Lacasse Y, et al. Lancet Respir Med. 2022 Nov;10(11):1029-1037. doi: 10.1016/S2213-2600(22)00179-5. Epub 2022 Jul 8. Lancet Respir Med. 2022. PMID: 35817074
When should we treat moderate hypoxaemia in patients with COPD?
Attaway A, Haouzi P. Attaway A, et al. Lancet Respir Med. 2022 Nov;10(11):e97. doi: 10.1016/S2213-2600(22)00355-1. Lancet Respir Med. 2022. PMID: 36332642 No abstract available.